Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

NDA FilingSelinexorRuxolitinibPositive

AI Analysis

Summary

Karyopharm reports continued progress toward an August sNDA submission for selinexor plus ruxolitinib in myelofibrosis under the Accelerated Approval Pathway. The submission is supported by Phase 3 SENTRY trial results presented at ASCO and EHA.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Planned sNDA submission under Accelerated Approval Pathway

Importance:7/10

Sentiment:

0.70

MyelofibrosisSelinexorRuxolitinibsNDAAccelerated ApprovalPhase 3SENTRY trialASCOEHA

Related Companies

$KPTI

Read the original article

Published by PR Newswire Biotech on August 13, 2026 11:30 AM

Read Original